Table II.

Tumor recognition of vaccine-specific CD8+ T cells in PBMC of patients with metastatic melanoma by tHLA staining and IFN-γ expression

PatientTreatment209-2M tHLA+ (% total CD8+)IFN-γ
IC-FACSqRT-PCRa
NoneA2+bA2A2+cA2A2+/A2−d
P1Pre0.060.000.010.000.001
Post 20.040.010.030.136
Post 40.040.020.020.100.01100
P2Pre2.460.770.660.240.011
Post 30.430.000.000.360.006
P3Pre0.060.060.080.050.092
Post 20.300.130.240.130.052
P4Pre0.080.070.080.000.005
Post 20.070.100.100.070.051
Post 40.270.200.360.100.0286
P5Pre0.000.000.000.000.001
Post 20.050.030.040.010.037
Post 40.600.190.550.370.136
P6Pre0.020.060.050.120.121
Post 40.170.110.110.330.335
Post 80.630.500.590.650.5911
Post 120.550.480.611.440.1610
P7Pre0.080.020.030.050.071
Post 40.080.090.090.250.092
Post 80.860.300.710.450.0783
P8Pre0.11NDeNDNDND1
Post 42.35NDNDNDND46
  • a IFN-γ mRNA per 106 CD8 mRNA copies in PBMC stimulated with the HLA-A2+ melanoma cell line 624.38-MEL. All patients with the exception of P3, P4, and P6 matched 624.38 only at HLA-A*0201. P3, P4, and P6 matched also A*0301. Reactivity associated with this allele was excluded by presenting data as fold IFN-γ expression by 624.38-MEL-stimulated PBMC over expression after stimulation with the HLA-A*0201, otherwise identical melanoma cell line 624.28-MEL. No HLA-B or Cw alleles matched 624-MEL lines.

  • b tHLA-A2+ Spearman’s ρ = 0.900, p = 0.001.

  • c IC-FACS-A2+ Spearman’s ρ = 0.785, p = 0.01.

  • d qRT-PCR-A2+ Spearman’s ρ = 0.531, p = 0.055.

  • e In this patient no sufficient material was available for this experiment.